JASON ZINN: Open Payments
NPI 1457350308 · HANOVER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,286 in 134 payments from 25 companies in 2025. Trend: 2023 $2,221 · 2024 $1,990 · 2025 $2,286
Food & beverage: $2,286
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $505 |
| Novo Nordisk Inc | 17 | $252 |
| AstraZeneca Pharmaceuticals LP | 12 | $242 |
| PFIZER INC. | 17 | $223 |
| Exact Sciences Corporation | 5 | $131 |
| Novartis Pharmaceuticals Corporation | 4 | $102 |
| Teva Pharmaceuticals USA, Inc. | 4 | $82 |
| Lilly USA, LLC | 4 | $71 |
| Vanda Pharmaceuticals Inc. | 3 | $67 |
| GlaxoSmithKline, LLC. | 4 | $65 |
Products named: VRAYLAR, AIRSUPRA, UBRELVY, QULIPTA, LEQVIO, Wegovy, Ozempic, BREZTRI.
Industry payments across PA — which companies pay providers there.
